Form 4: AXIM Biotechnologies Director Acquires Convertible Note

Blake Schroeder, a director at AXIM Biotechnologies, acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of common stock.

Summary

• On March 15, 2024, Blake Schroeder, a director of AXIM Biotechnologies, acquired a convertible note with a face value of $35,000.
• The note is convertible into 3,500,000 shares of AXIM Biotechnologies' common stock at a conversion price of $0.01 per share.
• Following the transaction, Schroeder directly owns 4,500,000 shares.
• The convertible note has an expiration date of March 1, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a transaction by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may be interested in this transaction as it provides insight into the actions of a company director.

Key Dates

Keywords

AXIM Biotechnologies, Convertible Note, Director, Blake Schroeder, Beneficial Ownership, Form 4, Securities